Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Will Repogeddon Make Gold Rally?

One of the most important recent developments in the world of finance was the September liquidity crisis in the U.S. repo market. As a reminder, the repo market is where borrowers borrow cash from lenders against collateral in the form of safe securities such as government bon...
Arkadiusz Sieron | November 8, 2019 |

Executing Our Vision, Achieving Our Global Potential: A Letter to Shareholders

Dear Fellow Legible Shareholders, I want to thank you for your continued support, faith, and trust in the Legible team to execute on our vision to revolutionize the global eBook marketplace for readers, publishers, and authors through our innovative eBook entertainment pl...
Featured Submission | April 13, 2022 |

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |

Fed Cut Equities Stimulus 86% This Week and Stocks Are Falling

What happens to the global markets when the US Fed begins to weaken stimulus activity and when the global markets must begin to function on their own? Are the global markets capable of sustaining current price levels without the Fed supporting them? A recent news article s...
Chris Vermeulen | May 1, 2020 |

Silver Offers A Golden Opportunity To Preserve Soon To Be Destroyed Value

The fundamentals for silver and gold are very strong, and with all the massive bailouts and stimulus, which have increased debt levels, they are just getting stronger. Until a significant portion of these debts is repaid or defaulted on, it would be foolish to talk about a to...
Hubert Moolman | July 3, 2020 |

Conversation with Katusa: The Biggest Short Squeeze in History

“We’re going to go through the biggest short squeeze in history, and it just so happens to be on the dollar.” Dear Reader, If you aren’t paying attention to the global squeeze of U.S. Dollars then you need to...
Marin Katusa | May 8, 2020 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Global Insanity Prevails

"Destroyers seize gold and leave to its owners a counterfeit pile of paper." —Ayn Rand Why don't we start things off a tad differently this evening? Let me relate to you all a parable from the Book of Quantitative Easing where all is good and noble in the world of gov...
Streetwise Reports | September 16, 2019 |

AOL, Inc. (AOL): Can it fly in the face of skepticism?

Late last week, analysts at Macquarie launched coverage of AOL, Inc. ( NYSE: AOL , Stock Forum ) with a "neutral" rating and a $27 price target, essentially implying that they don't expect the stock to move much higher in the near future. Nevertheless, unenthusiastic ra...
Andrea Kramer | October 28, 2012 |

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. Dublin, Ireland-based Avadel Pharmaceuticals Plc (AVDL:NASDAQ) , wh...
Streetwise Reports | September 24, 2019 |
1 2 3 4 5 6 7 8 9 10 ...